

Global NAD+ Intravenous Therapy Supply, Demand and Key Producers, 2026-2032

<https://marketpublishers.com/r/G689EC397252EN.html>

Date: February 2026

Pages: 127

Price: US\$ 4,480.00 (Single User License)

ID: G689EC397252EN

Abstracts

The global NAD+ Intravenous Therapy market size is expected to reach \$ 174 million by 2032, rising at a market growth of 8.1% CAGR during the forecast period (2026-2032). NAD+ IV Therapy is a wellness therapy that involves the intravenous administration of nicotinamide adenine dinucleotide (NAD+), a coenzyme crucial for cellular energy production and metabolic processes. This therapy is believed to boost energy levels, enhance cognitive function, and promote overall cellular repair by increasing NAD+ levels, which naturally decline with age.

1. Evidence-Driven Transition: NAD? IV Therapy Is Shifting from Concept-Based Anti-Aging to Clinically Validated Intervention

The most fundamental long-term trend for NAD? anti-aging intravenous therapy is its transition from a concept-driven wellness service toward an evidence-based clinical intervention. At present, most claimed benefits of NAD? IV?such as anti-fatigue, cognitive enhancement, metabolic optimization, and longevity?are primarily supported by mechanistic studies, animal models, or small observational trials, rather than large-scale randomized controlled trials (RCTs). As regulatory scrutiny increases and medical institutions demand higher scientific rigor, the industry will be forced to generate robust clinical evidence to validate therapeutic outcomes, define clear clinical indications, and demonstrate measurable improvements in objective biomarkers. Over time, NAD? IV is expected to evolve from a loosely defined ?anti-aging treatment? into a medically framed intervention with specific use cases, patient stratification, and standardized clinical endpoints.

2. Regulatory Tightening: NAD? IV Therapy Is Moving from a Gray Market into a Strongly Regulated Medical Framework

Another highly certain trend is the progressive tightening of regulatory oversight, which will push NAD? intravenous therapy out of its current semi-gray commercial zone and into a strictly regulated medical framework. In many markets today, NAD? IV is

delivered through medical spas, wellness clinics, or functional medicine centers, often without clearly approved indications, standardized drug registration status, or consistent compliance with pharmaceutical regulations. As governments strengthen control over injectable therapies, compounded drugs, and medical advertising, NAD⁺ IV services will increasingly be required to meet formal regulatory standards related to drug sourcing, sterile preparation, clinical justification, physician supervision, and liability management. This regulatory shift will significantly raise entry barriers and is expected to eliminate a large number of low-compliance providers, while favoring hospital systems, licensed clinics, and medically integrated institutions.

3. Safety and Quality Dominance: Sterility, Endotoxin Control, and Supply Chain Integrity Will Become Core Competitive Factors

Safety and pharmaceutical-grade quality control will become the central competitive axis of the NAD⁺ IV industry as it matures. Intravenous administration inherently carries higher systemic risks than oral supplementation, placing stringent demands on sterile manufacturing, endotoxin control, formulation stability, dosage consistency, and cold-chain logistics. Currently, the market exhibits significant heterogeneity in raw material sourcing, preparation standards, and clinical protocols, creating potential safety vulnerabilities. In the future, sustainable operators will be those capable of implementing GMP-level production systems, batch traceability, sterility validation, adverse-event monitoring, and standardized infusion procedures. As a result, NAD⁺ IV therapy will gradually resemble a pharmaceutical medical service rather than a consumer wellness product, with safety compliance itself becoming a major structural barrier to entry.

4. Product Pathway Differentiation: IV Administration Will Become a High-End Niche While Scalable Alternatives Expand

From a product strategy perspective, NAD⁺ IV therapy is structurally constrained from becoming a mass-market solution due to its high operational costs, time-intensive administration, medical dependency, and variability in patient tolerance. As research and commercialization of NAD⁺ precursors and alternative delivery methods continue to advance, market demand will increasingly shift toward more scalable, standardized, and consumer-friendly pathways. In this context, intravenous NAD⁺ will gradually reposition itself as a premium, specialized intervention within functional medicine, longevity clinics, and rehabilitation medicine, while larger market volumes will be captured by non-IV solutions. Long term, NAD⁺ IV is more likely to remain a precision medical tool for specific high-value scenarios rather than a mainstream anti-aging modality.

5. Business Model Evolution: From One-Time Anti-Aging Services to Longitudinal Medical Management Systems

The commercial model of NAD⁺ IV therapy is expected to evolve from transaction-based anti-aging packages toward longitudinal medical management systems centered on patient stratification and data feedback. As consumers become more

scientifically informed and regulators restrict exaggerated longevity claims, simple service-selling models will lose sustainability. Instead, leading providers will integrate NAD⁺ IV into broader functional medicine frameworks, supported by baseline diagnostics, biomarker tracking, patient segmentation, and outcome monitoring. In this emerging model, NAD⁺ IV is no longer positioned as a standalone product, but as one component within a personalized health optimization ecosystem, where long-term value is generated through continuous medical engagement, data accumulation, and outcome-based service delivery.

This report studies the global NAD⁺ Intravenous Therapy demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for NAD⁺ Intravenous Therapy, and provides market size (US\$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of NAD⁺ Intravenous Therapy that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global NAD⁺ Intravenous Therapy total market, 2021-2032, (USD Million)

Global NAD⁺ Intravenous Therapy total market by region & country, CAGR, 2021-2032, (USD Million)

U.S. VS China: NAD⁺ Intravenous Therapy total market, key domestic companies, and share, (USD Million)

Global NAD⁺ Intravenous Therapy revenue by player, revenue and market share 2021-2026, (USD Million)

Global NAD⁺ Intravenous Therapy total market by Type, CAGR, 2021-2032, (USD Million)

Global NAD⁺ Intravenous Therapy total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global NAD⁺ Intravenous Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include The Wellness Lab, Conciergemdla, Azivmedics, Reset IV, Thedripclub, Toronto Functional Medicine Centre, Mobileivmedics, Rocky Mountain Ivmedics, Premiumhealth, Effect Doctors, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world NAD⁺ Intravenous Therapy market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US\$

Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global NAD+ Intravenous Therapy Market, By Region:

United States

China

Europe

Japan

South Korea

ASEAN

India

Rest of World

Global NAD+ Intravenous Therapy Market, Segmentation by Type:

NAD+ Mixed Vitamin Injections

Pure NAD+ Injection

Global NAD+ Intravenous Therapy Market, Segmentation by Injection:

Single-use Injection Type

Recurring Injection Type

Others

Global NAD+ Intravenous Therapy Market, Segmentation by Dose:

Low-dose Type

Medium-dose Type

High-dose Type

Global NAD+ Intravenous Therapy Market, Segmentation by Application:

Clinic

Hospital

Others

Companies Profiled:

The Wellness Lab

Conciergemdla

Azivmedics

Reset IV

TheDripclub

Toronto Functional Medicine Centre

Mobileivmedics

Rocky Mountain Ivmedics

Premiumhealth

Effect Doctors

Nadclinic

Hydrate IV Bar

LIVV Natural

BioReset Medical

IV Boost UK

Key Questions Answered

1. How big is the global NAD+ Intravenous Therapy market?
2. What is the demand of the global NAD+ Intravenous Therapy market?
3. What is the year over year growth of the global NAD+ Intravenous Therapy market?
4. What is the total value of the global NAD+ Intravenous Therapy market?
5. Who are the Major Players in the global NAD+ Intravenous Therapy market?
6. What are the growth factors driving the market demand?

Contents

1 SUPPLY SUMMARY

- 1.1 NAD+ Intravenous Therapy Introduction
- 1.2 World NAD+ Intravenous Therapy Market Size & Forecast (2021 & 2025 & 2032)
- 1.3 World NAD+ Intravenous Therapy Total Market by Region (by Headquarter Location)
 - 1.3.1 World NAD+ Intravenous Therapy Market Size by Region (2021-2032), (by Headquarter Location)
 - 1.3.2 United States Based Company NAD+ Intravenous Therapy Revenue (2021-2032)
 - 1.3.3 China Based Company NAD+ Intravenous Therapy Revenue (2021-2032)
 - 1.3.4 Europe Based Company NAD+ Intravenous Therapy Revenue (2021-2032)
 - 1.3.5 Japan Based Company NAD+ Intravenous Therapy Revenue (2021-2032)
 - 1.3.6 South Korea Based Company NAD+ Intravenous Therapy Revenue (2021-2032)
 - 1.3.7 ASEAN Based Company NAD+ Intravenous Therapy Revenue (2021-2032)
 - 1.3.8 India Based Company NAD+ Intravenous Therapy Revenue (2021-2032)
- 1.4 Market Drivers, Restraints and Trends
 - 1.4.1 NAD+ Intravenous Therapy Market Drivers
 - 1.4.2 Factors Affecting Demand
 - 1.4.3 Major Market Trends

2 DEMAND SUMMARY

- 2.1 World NAD+ Intravenous Therapy Consumption Value (2021-2032)
- 2.2 World NAD+ Intravenous Therapy Consumption Value by Region
 - 2.2.1 World NAD+ Intravenous Therapy Consumption Value by Region (2021-2026)
 - 2.2.2 World NAD+ Intravenous Therapy Consumption Value Forecast by Region (2027-2032)
- 2.3 United States NAD+ Intravenous Therapy Consumption Value (2021-2032)
- 2.4 China NAD+ Intravenous Therapy Consumption Value (2021-2032)
- 2.5 Europe NAD+ Intravenous Therapy Consumption Value (2021-2032)
- 2.6 Japan NAD+ Intravenous Therapy Consumption Value (2021-2032)
- 2.7 South Korea NAD+ Intravenous Therapy Consumption Value (2021-2032)
- 2.8 ASEAN NAD+ Intravenous Therapy Consumption Value (2021-2032)
- 2.9 India NAD+ Intravenous Therapy Consumption Value (2021-2032)

3 WORLD NAD+ INTRAVENOUS THERAPY COMPANIES COMPETITIVE ANALYSIS

- 3.1 World NAD+ Intravenous Therapy Revenue by Player (2021-2026)
- 3.2 Industry Rank and Concentration Rate (CR)
 - 3.2.1 Global NAD+ Intravenous Therapy Industry Rank of Major Players
 - 3.2.2 Global Concentration Ratios (CR4) for NAD+ Intravenous Therapy in 2025
 - 3.2.3 Global Concentration Ratios (CR8) for NAD+ Intravenous Therapy in 2025
- 3.3 NAD+ Intravenous Therapy Company Evaluation Quadrant
- 3.4 NAD+ Intravenous Therapy Market: Overall Company Footprint Analysis
 - 3.4.1 NAD+ Intravenous Therapy Market: Region Footprint
 - 3.4.2 NAD+ Intravenous Therapy Market: Company Product Type Footprint
 - 3.4.3 NAD+ Intravenous Therapy Market: Company Product Application Footprint
- 3.5 Competitive Environment
 - 3.5.1 Historical Structure of the Industry
 - 3.5.2 Barriers of Market Entry
 - 3.5.3 Factors of Competition
- 3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

- 4.1 United States VS China: NAD+ Intravenous Therapy Revenue Comparison (by Headquarter Location)
 - 4.1.1 United States VS China: NAD+ Intravenous Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
 - 4.1.2 United States VS China: NAD+ Intravenous Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
- 4.2 United States Based Companies VS China Based Companies: NAD+ Intravenous Therapy Consumption Value Comparison
 - 4.2.1 United States VS China: NAD+ Intravenous Therapy Consumption Value Comparison (2021 & 2025 & 2032)
 - 4.2.2 United States VS China: NAD+ Intravenous Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
- 4.3 United States Based NAD+ Intravenous Therapy Companies and Market Share, 2021-2026
 - 4.3.1 United States Based NAD+ Intravenous Therapy Companies, Headquarters (States, Country)
 - 4.3.2 United States Based Companies NAD+ Intravenous Therapy Revenue, (2021-2026)
- 4.4 China Based Companies NAD+ Intravenous Therapy Revenue and Market Share,

2021-2026

4.4.1 China Based NAD+ Intravenous Therapy Companies, Company Headquarters (Province, Country)

4.4.2 China Based Companies NAD+ Intravenous Therapy Revenue, (2021-2026)

4.5 Rest of World Based NAD+ Intravenous Therapy Companies and Market Share, 2021-2026

4.5.1 Rest of World Based NAD+ Intravenous Therapy Companies, Headquarters (Province, Country)

4.5.2 Rest of World Based Companies NAD+ Intravenous Therapy Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World NAD+ Intravenous Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032

5.2 Segment Introduction by Type

5.2.1 NAD+ Mixed Vitamin Injections

5.2.2 Pure NAD+ Injection

5.3 Market Segment by Type

5.3.1 World NAD+ Intravenous Therapy Market Size by Type (2021-2026)

5.3.2 World NAD+ Intravenous Therapy Market Size by Type (2027-2032)

5.3.3 World NAD+ Intravenous Therapy Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY INJECTION

6.1 World NAD+ Intravenous Therapy Market Size Overview by Injection: 2021 VS 2025 VS 2032

6.2 Segment Introduction by Injection

6.2.1 Single-use Injection Type

6.2.2 Recurring Injection Type

6.2.3 Others

6.3 Market Segment by Injection

6.3.1 World NAD+ Intravenous Therapy Market Size by Injection (2021-2026)

6.3.2 World NAD+ Intravenous Therapy Market Size by Injection (2027-2032)

6.3.3 World NAD+ Intravenous Therapy Market Size Market Share by Injection (2027-2032)

7 MARKET ANALYSIS BY DOSE

7.1 World NAD+ Intravenous Therapy Market Size Overview by Dose: 2021 VS 2025 VS 2032

7.2 Segment Introduction by Dose

7.2.1 Low-dose Type

7.2.2 Medium-dose Type

7.2.3 High-dose Type

7.3 Market Segment by Dose

7.3.1 World NAD+ Intravenous Therapy Market Size by Dose (2021-2026)

7.3.2 World NAD+ Intravenous Therapy Market Size by Dose (2027-2032)

7.3.3 World NAD+ Intravenous Therapy Market Size Market Share by Dose (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World NAD+ Intravenous Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032

8.2 Segment Introduction by Application

8.2.1 Clinic

8.2.2 Hospital

8.2.3 Others

8.3 Market Segment by Application

8.3.1 World NAD+ Intravenous Therapy Market Size by Application (2021-2026)

8.3.2 World NAD+ Intravenous Therapy Market Size by Application (2027-2032)

8.3.3 World NAD+ Intravenous Therapy Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 The Wellness Lab

9.1.1 The Wellness Lab Details

9.1.2 The Wellness Lab Major Business

9.1.3 The Wellness Lab NAD+ Intravenous Therapy Product and Services

9.1.4 The Wellness Lab NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)

9.1.5 The Wellness Lab Recent Developments/Updates

9.1.6 The Wellness Lab Competitive Strengths & Weaknesses

9.2 Conciergemdl

9.2.1 Conciergemdl Details

- 9.2.2 Conciergemdlá Major Business
- 9.2.3 Conciergemdlá NAD+ Intravenous Therapy Product and Services
- 9.2.4 Conciergemdlá NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 9.2.5 Conciergemdlá Recent Developments/Updates
- 9.2.6 Conciergemdlá Competitive Strengths & Weaknesses
- 9.3 Azivmedics
 - 9.3.1 Azivmedics Details
 - 9.3.2 Azivmedics Major Business
 - 9.3.3 Azivmedics NAD+ Intravenous Therapy Product and Services
 - 9.3.4 Azivmedics NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 9.3.5 Azivmedics Recent Developments/Updates
 - 9.3.6 Azivmedics Competitive Strengths & Weaknesses
- 9.4 Reset IV
 - 9.4.1 Reset IV Details
 - 9.4.2 Reset IV Major Business
 - 9.4.3 Reset IV NAD+ Intravenous Therapy Product and Services
 - 9.4.4 Reset IV NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 9.4.5 Reset IV Recent Developments/Updates
 - 9.4.6 Reset IV Competitive Strengths & Weaknesses
- 9.5 Thedripclub
 - 9.5.1 Thedripclub Details
 - 9.5.2 Thedripclub Major Business
 - 9.5.3 Thedripclub NAD+ Intravenous Therapy Product and Services
 - 9.5.4 Thedripclub NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 9.5.5 Thedripclub Recent Developments/Updates
 - 9.5.6 Thedripclub Competitive Strengths & Weaknesses
- 9.6 Toronto Functional Medicine Centre
 - 9.6.1 Toronto Functional Medicine Centre Details
 - 9.6.2 Toronto Functional Medicine Centre Major Business
 - 9.6.3 Toronto Functional Medicine Centre NAD+ Intravenous Therapy Product and Services
 - 9.6.4 Toronto Functional Medicine Centre NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 9.6.5 Toronto Functional Medicine Centre Recent Developments/Updates
 - 9.6.6 Toronto Functional Medicine Centre Competitive Strengths & Weaknesses

9.7 Mobileivmedics

9.7.1 Mobileivmedics Details

9.7.2 Mobileivmedics Major Business

9.7.3 Mobileivmedics NAD+ Intravenous Therapy Product and Services

9.7.4 Mobileivmedics NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)

9.7.5 Mobileivmedics Recent Developments/Updates

9.7.6 Mobileivmedics Competitive Strengths & Weaknesses

9.8 Rocky Mountain Ivmedics

9.8.1 Rocky Mountain Ivmedics Details

9.8.2 Rocky Mountain Ivmedics Major Business

9.8.3 Rocky Mountain Ivmedics NAD+ Intravenous Therapy Product and Services

9.8.4 Rocky Mountain Ivmedics NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)

9.8.5 Rocky Mountain Ivmedics Recent Developments/Updates

9.8.6 Rocky Mountain Ivmedics Competitive Strengths & Weaknesses

9.9 Premiumhealth

9.9.1 Premiumhealth Details

9.9.2 Premiumhealth Major Business

9.9.3 Premiumhealth NAD+ Intravenous Therapy Product and Services

9.9.4 Premiumhealth NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)

9.9.5 Premiumhealth Recent Developments/Updates

9.9.6 Premiumhealth Competitive Strengths & Weaknesses

9.10 Effect Doctors

9.10.1 Effect Doctors Details

9.10.2 Effect Doctors Major Business

9.10.3 Effect Doctors NAD+ Intravenous Therapy Product and Services

9.10.4 Effect Doctors NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)

9.10.5 Effect Doctors Recent Developments/Updates

9.10.6 Effect Doctors Competitive Strengths & Weaknesses

9.11 Nadclinic

9.11.1 Nadclinic Details

9.11.2 Nadclinic Major Business

9.11.3 Nadclinic NAD+ Intravenous Therapy Product and Services

9.11.4 Nadclinic NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)

9.11.5 Nadclinic Recent Developments/Updates

- 9.11.6 Nadclinic Competitive Strengths & Weaknesses
- 9.12 Hydrate IV Bar
 - 9.12.1 Hydrate IV Bar Details
 - 9.12.2 Hydrate IV Bar Major Business
 - 9.12.3 Hydrate IV Bar NAD+ Intravenous Therapy Product and Services
 - 9.12.4 Hydrate IV Bar NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 9.12.5 Hydrate IV Bar Recent Developments/Updates
 - 9.12.6 Hydrate IV Bar Competitive Strengths & Weaknesses
- 9.13 LIVV Natural
 - 9.13.1 LIVV Natural Details
 - 9.13.2 LIVV Natural Major Business
 - 9.13.3 LIVV Natural NAD+ Intravenous Therapy Product and Services
 - 9.13.4 LIVV Natural NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 9.13.5 LIVV Natural Recent Developments/Updates
 - 9.13.6 LIVV Natural Competitive Strengths & Weaknesses
- 9.14 BioReset Medical
 - 9.14.1 BioReset Medical Details
 - 9.14.2 BioReset Medical Major Business
 - 9.14.3 BioReset Medical NAD+ Intravenous Therapy Product and Services
 - 9.14.4 BioReset Medical NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 9.14.5 BioReset Medical Recent Developments/Updates
 - 9.14.6 BioReset Medical Competitive Strengths & Weaknesses
- 9.15 IV Boost UK
 - 9.15.1 IV Boost UK Details
 - 9.15.2 IV Boost UK Major Business
 - 9.15.3 IV Boost UK NAD+ Intravenous Therapy Product and Services
 - 9.15.4 IV Boost UK NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 9.15.5 IV Boost UK Recent Developments/Updates
 - 9.15.6 IV Boost UK Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

- 10.1 NAD+ Intravenous Therapy Industry Chain
- 10.2 NAD+ Intravenous Therapy Upstream Analysis
- 10.3 NAD+ Intravenous Therapy Midstream Analysis

10.4 NAD+ Intravenous Therapy Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. World NAD+ Intravenous Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Table 2. World NAD+ Intravenous Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)

Table 3. World NAD+ Intravenous Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)

Table 4. World NAD+ Intravenous Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)

Table 5. World NAD+ Intravenous Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)

Table 6. Major Market Trends

Table 7. World NAD+ Intravenous Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)

Table 8. World NAD+ Intravenous Therapy Consumption Value by Region (2021-2026) & (USD Million)

Table 9. World NAD+ Intravenous Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)

Table 10. World NAD+ Intravenous Therapy Revenue by Player (2021-2026) & (USD Million)

Table 11. Revenue Market Share of Key NAD+ Intravenous Therapy Players in 2025

Table 12. World NAD+ Intravenous Therapy Industry Rank of Major Player, Based on Revenue in 2025

Table 13. Global NAD+ Intravenous Therapy Company Evaluation Quadrant

Table 14. Head Office of Key NAD+ Intravenous Therapy Players

Table 15. NAD+ Intravenous Therapy Market: Company Product Type Footprint

Table 16. NAD+ Intravenous Therapy Market: Company Product Application Footprint

Table 17. NAD+ Intravenous Therapy Mergers & Acquisitions Activity

Table 18. United States VS China NAD+ Intravenous Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 19. United States VS China NAD+ Intravenous Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)

Table 20. United States Based NAD+ Intravenous Therapy Companies, Headquarters (States, Country)

Table 21. United States Based Companies NAD+ Intravenous Therapy Revenue, (2021-2026) & (USD Million)

Table 22. United States Based Companies NAD+ Intravenous Therapy Revenue Market Share (2021-2026)

Table 23. China Based NAD+ Intravenous Therapy Companies, Headquarters (Province, Country)

Table 24. China Based Companies NAD+ Intravenous Therapy Revenue, (2021-2026) & (USD Million)

Table 25. China Based Companies NAD+ Intravenous Therapy Revenue Market Share (2021-2026)

Table 26. Rest of World Based NAD+ Intravenous Therapy Companies, Headquarters (Province, Country)

Table 27. Rest of World Based Companies NAD+ Intravenous Therapy Revenue (2021-2026) & (USD Million)

Table 28. Rest of World Based Companies NAD+ Intravenous Therapy Revenue Market Share (2021-2026)

Table 29. World NAD+ Intravenous Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032

Table 30. World NAD+ Intravenous Therapy Market Size Value by Type (2021-2026) & (USD Million)

Table 31. World NAD+ Intravenous Therapy Market Size by Type (2027-2032) & (USD Million)

Table 32. World NAD+ Intravenous Therapy Market Size by Injection, (USD Million), 2021 & 2025 & 2032

Table 33. World NAD+ Intravenous Therapy Market Size Value by Injection (2021-2026) & (USD Million)

Table 34. World NAD+ Intravenous Therapy Market Size by Injection (2027-2032) & (USD Million)

Table 35. World NAD+ Intravenous Therapy Market Size by Dose, (USD Million), 2021 & 2025 & 2032

Table 36. World NAD+ Intravenous Therapy Market Size Value by Dose (2021-2026) & (USD Million)

Table 37. World NAD+ Intravenous Therapy Market Size by Dose (2027-2032) & (USD Million)

Table 38. World NAD+ Intravenous Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032

Table 39. World NAD+ Intravenous Therapy Market Size by Application (2021-2026) & (USD Million)

Table 40. World NAD+ Intravenous Therapy Market Size by Application (2027-2032) & (USD Million)

Table 41. The Wellness Lab Basic Information, Manufacturing Base and Competitors

Table 42. The Wellness Lab Major Business

Table 43. The Wellness Lab NAD+ Intravenous Therapy Product and Services

Table 44. The Wellness Lab NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 45. The Wellness Lab Recent Developments/Updates

Table 46. The Wellness Lab Competitive Strengths & Weaknesses

Table 47. Conciergemdla Basic Information, Manufacturing Base and Competitors

Table 48. Conciergemdla Major Business

Table 49. Conciergemdla NAD+ Intravenous Therapy Product and Services

Table 50. Conciergemdla NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 51. Conciergemdla Recent Developments/Updates

Table 52. Conciergemdla Competitive Strengths & Weaknesses

Table 53. Azivmedics Basic Information, Manufacturing Base and Competitors

Table 54. Azivmedics Major Business

Table 55. Azivmedics NAD+ Intravenous Therapy Product and Services

Table 56. Azivmedics NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 57. Azivmedics Recent Developments/Updates

Table 58. Azivmedics Competitive Strengths & Weaknesses

Table 59. Reset IV Basic Information, Manufacturing Base and Competitors

Table 60. Reset IV Major Business

Table 61. Reset IV NAD+ Intravenous Therapy Product and Services

Table 62. Reset IV NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 63. Reset IV Recent Developments/Updates

Table 64. Reset IV Competitive Strengths & Weaknesses

Table 65. Thedripclub Basic Information, Manufacturing Base and Competitors

Table 66. Thedripclub Major Business

Table 67. Thedripclub NAD+ Intravenous Therapy Product and Services

Table 68. Thedripclub NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 69. Thedripclub Recent Developments/Updates

Table 70. Thedripclub Competitive Strengths & Weaknesses

Table 71. Toronto Functional Medicine Centre Basic Information, Manufacturing Base and Competitors

Table 72. Toronto Functional Medicine Centre Major Business

Table 73. Toronto Functional Medicine Centre NAD+ Intravenous Therapy Product and Services

Table 74. Toronto Functional Medicine Centre NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 75. Toronto Functional Medicine Centre Recent Developments/Updates

Table 76. Toronto Functional Medicine Centre Competitive Strengths & Weaknesses

Table 77. Mobileivmedics Basic Information, Manufacturing Base and Competitors

Table 78. Mobileivmedics Major Business

Table 79. Mobileivmedics NAD+ Intravenous Therapy Product and Services

Table 80. Mobileivmedics NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 81. Mobileivmedics Recent Developments/Updates

Table 82. Mobileivmedics Competitive Strengths & Weaknesses

Table 83. Rocky Mountain Ivmedics Basic Information, Manufacturing Base and Competitors

Table 84. Rocky Mountain Ivmedics Major Business

Table 85. Rocky Mountain Ivmedics NAD+ Intravenous Therapy Product and Services

Table 86. Rocky Mountain Ivmedics NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 87. Rocky Mountain Ivmedics Recent Developments/Updates

Table 88. Rocky Mountain Ivmedics Competitive Strengths & Weaknesses

Table 89. Premiumhealth Basic Information, Manufacturing Base and Competitors

Table 90. Premiumhealth Major Business

Table 91. Premiumhealth NAD+ Intravenous Therapy Product and Services

Table 92. Premiumhealth NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 93. Premiumhealth Recent Developments/Updates

Table 94. Premiumhealth Competitive Strengths & Weaknesses

Table 95. Effect Doctors Basic Information, Manufacturing Base and Competitors

Table 96. Effect Doctors Major Business

Table 97. Effect Doctors NAD+ Intravenous Therapy Product and Services

Table 98. Effect Doctors NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 99. Effect Doctors Recent Developments/Updates

Table 100. Effect Doctors Competitive Strengths & Weaknesses

Table 101. Nadclinic Basic Information, Manufacturing Base and Competitors

Table 102. Nadclinic Major Business

Table 103. Nadclinic NAD+ Intravenous Therapy Product and Services

Table 104. Nadclinic NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

Table 105. Nadclinic Recent Developments/Updates

- Table 106. Nadclinic Competitive Strengths & Weaknesses
- Table 107. Hydrate IV Bar Basic Information, Manufacturing Base and Competitors
- Table 108. Hydrate IV Bar Major Business
- Table 109. Hydrate IV Bar NAD+ Intravenous Therapy Product and Services
- Table 110. Hydrate IV Bar NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 111. Hydrate IV Bar Recent Developments/Updates
- Table 112. Hydrate IV Bar Competitive Strengths & Weaknesses
- Table 113. LIVV Natural Basic Information, Manufacturing Base and Competitors
- Table 114. LIVV Natural Major Business
- Table 115. LIVV Natural NAD+ Intravenous Therapy Product and Services
- Table 116. LIVV Natural NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 117. LIVV Natural Recent Developments/Updates
- Table 118. LIVV Natural Competitive Strengths & Weaknesses
- Table 119. BioReset Medical Basic Information, Manufacturing Base and Competitors
- Table 120. BioReset Medical Major Business
- Table 121. BioReset Medical NAD+ Intravenous Therapy Product and Services
- Table 122. BioReset Medical NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 123. BioReset Medical Recent Developments/Updates
- Table 124. BioReset Medical Competitive Strengths & Weaknesses
- Table 125. IV Boost UK Basic Information, Manufacturing Base and Competitors
- Table 126. IV Boost UK Major Business
- Table 127. IV Boost UK NAD+ Intravenous Therapy Product and Services
- Table 128. IV Boost UK NAD+ Intravenous Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
- Table 129. IV Boost UK Recent Developments/Updates
- Table 130. IV Boost UK Competitive Strengths & Weaknesses
- Table 131. Global Key Players of NAD+ Intravenous Therapy Upstream (Raw Materials)
- Table 132. Global NAD+ Intravenous Therapy Typical Customers

List Of Figures

LIST OF FIGURES

Figure 1. NAD+ Intravenous Therapy Picture

Figure 2. World NAD+ Intravenous Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)

Figure 3. World NAD+ Intravenous Therapy Total Revenue (2021-2032) & (USD Million)

Figure 4. World NAD+ Intravenous Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)

Figure 5. World NAD+ Intravenous Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)

Figure 6. United States Based Company NAD+ Intravenous Therapy Revenue (2021-2032) & (USD Million)

Figure 7. China Based Company NAD+ Intravenous Therapy Revenue (2021-2032) & (USD Million)

Figure 8. Europe Based Company NAD+ Intravenous Therapy Revenue (2021-2032) & (USD Million)

Figure 9. Japan Based Company NAD+ Intravenous Therapy Revenue (2021-2032) & (USD Million)

Figure 10. South Korea Based Company NAD+ Intravenous Therapy Revenue (2021-2032) & (USD Million)

Figure 11. ASEAN Based Company NAD+ Intravenous Therapy Revenue (2021-2032) & (USD Million)

Figure 12. India Based Company NAD+ Intravenous Therapy Revenue (2021-2032) & (USD Million)

Figure 13. NAD+ Intravenous Therapy Market Drivers

Figure 14. Factors Affecting Demand

Figure 15. World NAD+ Intravenous Therapy Consumption Value (2021-2032) & (USD Million)

Figure 16. World NAD+ Intravenous Therapy Consumption Value Market Share by Region (2021-2032)

Figure 17. United States NAD+ Intravenous Therapy Consumption Value (2021-2032) & (USD Million)

Figure 18. China NAD+ Intravenous Therapy Consumption Value (2021-2032) & (USD Million)

Figure 19. Europe NAD+ Intravenous Therapy Consumption Value (2021-2032) & (USD Million)

Figure 20. Japan NAD+ Intravenous Therapy Consumption Value (2021-2032) & (USD Million)

Million)

Figure 21. South Korea NAD+ Intravenous Therapy Consumption Value (2021-2032) & (USD Million)

Figure 22. ASEAN NAD+ Intravenous Therapy Consumption Value (2021-2032) & (USD Million)

Figure 23. India NAD+ Intravenous Therapy Consumption Value (2021-2032) & (USD Million)

Figure 24. Producer Shipments of NAD+ Intravenous Therapy by Player Revenue (\$MM) and Market Share (%): 2025

Figure 25. Global Four-firm Concentration Ratios (CR4) for NAD+ Intravenous Therapy Markets in 2025

Figure 26. Global Four-firm Concentration Ratios (CR8) for NAD+ Intravenous Therapy Markets in 2025

Figure 27. United States VS China: NAD+ Intravenous Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)

Figure 28. United States VS China: NAD+ Intravenous Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)

Figure 29. World NAD+ Intravenous Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032

Figure 30. World NAD+ Intravenous Therapy Market Size Market Share by Type in 2025

Figure 31. NAD+ Mixed Vitamin Injections

Figure 32. Pure NAD+ Injection

Figure 33. World NAD+ Intravenous Therapy Market Size Market Share by Type (2021-2032)

Figure 34. World NAD+ Intravenous Therapy Market Size by Injection, (USD Million), 2021 & 2025 & 2032

Figure 35. World NAD+ Intravenous Therapy Market Size Market Share by Injection in 2025

Figure 36. Single-use Injection Type

Figure 37. Recurring Injection Type

Figure 38. Others

Figure 39. World NAD+ Intravenous Therapy Market Size Market Share by Injection (2021-2032)

Figure 40. World NAD+ Intravenous Therapy Market Size by Dose, (USD Million), 2021 & 2025 & 2032

Figure 41. World NAD+ Intravenous Therapy Market Size Market Share by Dose in 2025

Figure 42. Low-dose Type

Figure 43. Medium-dose Type

Figure 44. High-dose Type

Figure 45. World NAD+ Intravenous Therapy Market Size Market Share by Dose (2021-2032)

Figure 46. World NAD+ Intravenous Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032

Figure 47. World NAD+ Intravenous Therapy Market Size Market Share by Application in 2025

Figure 48. Clinic

Figure 49. Hospital

Figure 50. Others

Figure 51. World NAD+ Intravenous Therapy Market Size Market Share by Application (2021-2032)

Figure 52. NAD+ Intravenous Therapy Industrial Chain

Figure 53. Methodology

Figure 54. Research Process and Data Source

I would like to order

Product name: Global NAD+ Intravenous Therapy Supply, Demand and Key Producers, 2026-2032

Product link: <https://marketpublishers.com/r/G689EC397252EN.html>

Price: US\$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G689EC397252EN.html>